140 related articles for article (PubMed ID: 22886699)
21. FGF23, Hypophosphatemia, and Emerging Treatments.
Imel EA; Biggin A; Schindeler A; Munns CF
JBMR Plus; 2019 Aug; 3(8):e10190. PubMed ID: 31485552
[TBL] [Abstract][Full Text] [Related]
22. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
Haffner D; Emma F; Eastwood DM; Duplan MB; Bacchetta J; Schnabel D; Wicart P; Bockenhauer D; Santos F; Levtchenko E; Harvengt P; Kirchhoff M; Di Rocco F; Chaussain C; Brandi ML; Savendahl L; Briot K; Kamenicky P; Rejnmark L; Linglart A
Nat Rev Nephrol; 2019 Jul; 15(7):435-455. PubMed ID: 31068690
[TBL] [Abstract][Full Text] [Related]
23. FGF23 and its role in X-linked hypophosphatemia-related morbidity.
Beck-Nielsen SS; Mughal Z; Haffner D; Nilsson O; Levtchenko E; Ariceta G; de Lucas Collantes C; Schnabel D; Jandhyala R; Mäkitie O
Orphanet J Rare Dis; 2019 Feb; 14(1):58. PubMed ID: 30808384
[TBL] [Abstract][Full Text] [Related]
24. FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.
Smith ER; Tan SJ; Holt SG; Hewitson TD
Sci Rep; 2017 Jun; 7(1):3345. PubMed ID: 28611350
[TBL] [Abstract][Full Text] [Related]
25. A novel auditory ossicles membrane and the development of conductive hearing loss in Dmp1-null mice.
Lv K; Huang H; Yi X; Chertoff ME; Li C; Yuan B; Hinton RJ; Feng JQ
Bone; 2017 Oct; 103():39-46. PubMed ID: 28603080
[TBL] [Abstract][Full Text] [Related]
26. Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition.
Yamamoto H; Ramos-Molina B; Lick AN; Prideaux M; Albornoz V; Bonewald L; Lindberg I
Bone; 2016 Mar; 84():120-130. PubMed ID: 26746780
[TBL] [Abstract][Full Text] [Related]
27. Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23.
Ren Y; Han X; Jing Y; Yuan B; Ke H; Liu M; Feng JQ
Matrix Biol; 2016; 52-54():151-161. PubMed ID: 26721590
[TBL] [Abstract][Full Text] [Related]
28. Family with sequence similarity member 20C is the primary but not the only kinase for the small-integrin-binding ligand N-linked glycoproteins in bone.
Yang X; Yan W; Tian Y; Ma P; Opperman LA; Wang X
FASEB J; 2016 Jan; 30(1):121-8. PubMed ID: 26324849
[TBL] [Abstract][Full Text] [Related]
29. A unified model for bone-renal mineral and energy metabolism.
Rowe PS
Curr Opin Pharmacol; 2015 Jun; 22():64-71. PubMed ID: 25880364
[TBL] [Abstract][Full Text] [Related]
30. FGF23 is endogenously phosphorylated in bone cells.
Lindberg I; Pang HW; Stains JP; Clark D; Yang AJ; Bonewald L; Li KZ
J Bone Miner Res; 2015 Mar; 30(3):449-54. PubMed ID: 25195776
[TBL] [Abstract][Full Text] [Related]
31. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
32. Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis.
White KE; Hum JM; Econs MJ
Curr Osteoporos Rep; 2014 Sep; 12(3):252-62. PubMed ID: 24980542
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor 23 in acute kidney injury.
Christov M
Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):340-5. PubMed ID: 24848938
[TBL] [Abstract][Full Text] [Related]
34. PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism.
Zelenchuk LV; Hedge AM; Rowe PS
PLoS One; 2014; 9(5):e97326. PubMed ID: 24839967
[TBL] [Abstract][Full Text] [Related]
35. Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp mice.
Miyagawa K; Yamazaki M; Kawai M; Nishino J; Koshimizu T; Ohata Y; Tachikawa K; Mikuni-Takagaki Y; Kogo M; Ozono K; Michigami T
PLoS One; 2014; 9(4):e93840. PubMed ID: 24710520
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic management of hypophosphatemic rickets from infancy to adulthood.
Linglart A; Biosse-Duplan M; Briot K; Chaussain C; Esterle L; Guillaume-Czitrom S; Kamenicky P; Nevoux J; Prié D; Rothenbuhler A; Wicart P; Harvengt P
Endocr Connect; 2014; 3(1):R13-30. PubMed ID: 24550322
[TBL] [Abstract][Full Text] [Related]
37. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.
Imel EA; Gray AK; Padgett LR; Econs MJ
Bone; 2014 Mar; 60():87-92. PubMed ID: 24325979
[TBL] [Abstract][Full Text] [Related]
38. The rachitic tooth.
Foster BL; Nociti FH; Somerman MJ
Endocr Rev; 2014 Feb; 35(1):1-34. PubMed ID: 23939820
[TBL] [Abstract][Full Text] [Related]
39. Extracellular matrix mineralization in periodontal tissues: Noncollagenous matrix proteins, enzymes, and relationship to hypophosphatasia and X-linked hypophosphatemia.
McKee MD; Hoac B; Addison WN; Barros NM; Millán JL; Chaussain C
Periodontol 2000; 2013 Oct; 63(1):102-22. PubMed ID: 23931057
[TBL] [Abstract][Full Text] [Related]
40. Hypophosphatemic rickets due to perturbations in renal tubular function.
Penido MG; Alon US
Pediatr Nephrol; 2014 Mar; 29(3):361-73. PubMed ID: 23636577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
